Skip to main content
Clinical Trials/NCT03638726
NCT03638726
Unknown
Phase 4

Combined Subconjunctival Atropine and Intracameral Epinephrine Injection for Pupil Dilation in Phacoemulsification Under Peribulbar Anesthesia.

Dar El Oyoun Hospital1 site in 1 country40 target enrollmentSeptember 28, 2018

Overview

Phase
Phase 4
Intervention
Atropine sulfate and epinephrine
Conditions
Cataract
Sponsor
Dar El Oyoun Hospital
Enrollment
40
Locations
1
Primary Endpoint
Intraoperative pupil diameter
Last Updated
7 years ago

Overview

Brief Summary

Mydriatic eye drops are routinely used before phacoemulsification but they are not free of drawbacks. Several alternatives were tried to overcome their limitations.

Detailed Description

The study will include 20 patients with bilateral cataract (40 eyes). The experimental group will include eyes for which a new injectable mydriatic combination are used to dilate the pupil. The control group will include cases where standard mydriatic eye drops are used.

Registry
clinicaltrials.gov
Start Date
September 28, 2018
End Date
June 2019
Last Updated
7 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Dr. Ashraf Nossair, MD

Associate Professor of Ophthalmology, Cairo University

Dar El Oyoun Hospital

Eligibility Criteria

Inclusion Criteria

  • Cases of bilateral visually significant cataract

Exclusion Criteria

  • Poor pupil dilation(less than 6 mm diameter).
  • History of previous eye surgery or trauma
  • History of use of eye drops affecting pupil size such as pilocarpine.
  • Known drug allergy to cyclopentolate,phenylephrine, atropine sulfate or epinephrine.
  • Pediatric age group (less than 18 years old).
  • Pupil abnormalities, such as anisocoria or neurological disorders.
  • Associated glaucoma, uveitis, corneal, retinal or optic nerve disease.
  • Cases scheduled for phacoemulsification under general anaesthesia (to exclude possible ocular and systemic effects or interactions of anaesthetic agents).
  • Patients with bleeding tendency or on anti-coagulant therapy (because peribulbar and subconjunctival injections are used).

Arms & Interventions

Atropine sulfate and Epinephrine

Perioperative pupil dilation is achieved by combined use of subconjunctival Atropine sulfate 0.6 mg ( parasympathetic antagonist) and intracameral Epinephrine 1:100000 ( sympathetic agonist).

Intervention: Atropine sulfate and epinephrine

Topical cyclopentolate and phenylephrine

Preoperative pupil dilation was achieved using topical cyclopentolate and phenylephrine.

Intervention: Topical cyclopentolate and phenylephrine

Outcomes

Primary Outcomes

Intraoperative pupil diameter

Time Frame: 1 day

Intraoperative pupil diameter measurements of involved eye in mm

Secondary Outcomes

  • Postoperative complications(Starting from first postoperative day till one month.)
  • Postoperative corneal thickness(1 month after surgery)
  • Postoperative corneal endothelial density(1 month after surgery)
  • Postoperative pupil diameter(one day, one week and one month after surgery)
  • Postoperative visual acuity(One day, one week and one month after surgery)
  • Postoperative intraocular pressure (IOP)(One day, one week and one month after surgery)

Study Sites (1)

Loading locations...

Similar Trials